Cure My Disease

Don't miss your cure!

 Log in / Sign up

Peptide vs whole protein: which formula boosts absorption in ICU patients?

NCT ID NCT07709611

Knowledge-focused Sponsor: Shanghai 10th People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This trial tests whether short peptide enteral nutrition formulas help ICU patients with a high risk of pancreatic exocrine insufficiency absorb protein better than standard whole protein formulas. Researchers will measure amino acid levels and other markers in 250 critically ill adults. The goal is to find the most efficient way to deliver protein to these vulnerable patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
short peptide enteral nutrition formula and whole protein enteral nutrition formula
What this could lead to
If peptide formulas prove better, this could improve protein absorption and recovery for critically ill patients with pancreatic issues.
What could go wrong
This is a single-center trial with 250 participants, so results may not apply broadly. The benefit may be small or not clinically meaningful.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 250 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age≥ 18 years old, no gender restriction; * Meet the criteria for high-risk groups for PEI; * AGI≤ Class II, hemodynamically stable, meeting EN initiation criteria; * Estimated duration of enteral nutrition support therapy: ≥7 days; * The subject or their legally authorized family member must sign the informed consent form Exclusion Criteria: * Patients who have been clearly diagnosed with PEI or chronic persistent PEI; * Patients who have contraindications to enteral nutrition therapy; * Patients with severely impaired liver or kidney function; * Patients who suffer from amino acid metabolism disorders, severe malnutrition, or cachexia; * Patients who have received pancreatic enzyme replacement therapy or taken any medications that may affect protein absorption within 7 days prior to enrollment; * Patients for whom the expected length of ICU stay is less than 7 days; * Pregnant or lactating women, as well as patients with mental illnesses; * Patients who are allergic to any component of the study medication.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Enteral nutrition feeding are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Enteral nutrition feeding High-risk patients with pancreatic exocrine insufficiency

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Tongji Hospital

    Shanghai, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.